Difficulty: Medium
Average Score: 90%
Practice
Emetine is now used only as a reserve drug for amoebiasis because
Correct answer
C
Rationale
Emetine is now used only as a reserve drug for amoebiasis because of its cardiotoxic potential. This means that it can have harmful effects on the heart, potentially leading to serious cardiac issues. This side effect has limited its use and relegated it to a secondary option when other treatments, such as metronidazole, are not effective or feasible.
Option A, stating that emetine is less effective than metronidazole, is incorrect. While effectiveness is a consideration in treatment choices, the primary reason for emetine's limited use is its safety profile, particularly its cardiotoxicity.
Option B, suggesting that emetine produces a slower response than metronidazole, is also incorrect. The speed of response is important in treating infections, but the main concern with emetine lies in its adverse effects rather than its efficacy timeline.
Option D, claiming that emetine does not clear stools of amoebic cysts, is not the primary reason for its limited use. While clearance of the causative agent is essential, the potential harm from emetine's cardiotoxicity is the critical factor in its restricted use.
Educationally, understanding the rationale behind treatment choices is crucial for healthcare providers. In this case, knowing the specific reason why emetine is no longer a first-line treatment for amoebiasis can help in making informed decisions when managing patients with such infections. It also underscores the importance of weighing the benefits and risks of medications in clinical practice.
Option A, stating that emetine is less effective than metronidazole, is incorrect. While effectiveness is a consideration in treatment choices, the primary reason for emetine's limited use is its safety profile, particularly its cardiotoxicity.
Option B, suggesting that emetine produces a slower response than metronidazole, is also incorrect. The speed of response is important in treating infections, but the main concern with emetine lies in its adverse effects rather than its efficacy timeline.
Option D, claiming that emetine does not clear stools of amoebic cysts, is not the primary reason for its limited use. While clearance of the causative agent is essential, the potential harm from emetine's cardiotoxicity is the critical factor in its restricted use.
Educationally, understanding the rationale behind treatment choices is crucial for healthcare providers. In this case, knowing the specific reason why emetine is no longer a first-line treatment for amoebiasis can help in making informed decisions when managing patients with such infections. It also underscores the importance of weighing the benefits and risks of medications in clinical practice.